Literature DB >> 3653195

Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.

R Lewensohn1, J Hansson, U Ringborg, H Ehrsson.   

Abstract

DNA interstrand, as well as DNA protein cross-linking, was more efficient in phytohaemagglutinin-stimulated human lymphocytes exposed to m-L-sarcolysin as compared to melphalan at equivalent concentrations of the drug. The cellular uptake of m-L-sarcolysin was more efficient as compared to melphalan. With peptichemio, a mixture of 6 peptides containing m-L-sarcolysin, an intermediate level of DNA cross-linking was found. The differences in DNA cross-linking between the 3 drugs were parallel to differences in cytotoxicity. Peptichemio has been ascribed anti-metabolic properties in addition to the alkylating properties conferred by its m-L-sarcolysin content. In the phytohaemagglutinin-stimulated lymphocytes, however, the effect of peptichemio seems linked to its capacity for DNA cross-linking.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653195     DOI: 10.1016/0277-5379(87)90279-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.

Authors:  Jyothi Matharu; Jun Oki; David R Worthen; Quentin R Smith; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

2.  Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).

Authors:  F Verlicchi; S Boschi; G Visani; A Guidi; P Tosi; M Cavo; S Tura
Journal:  Blut       Date:  1990-11

3.  Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.

Authors:  H Ehrsson; R Lewensohn; I Wallin; M Hellström; G Merlini; B Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.